Pipeline Insight: Cancer Vaccines and Cell Therapies

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-04-04

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Unmet need across the cancer market is high, with most therapies conferring low levels of specificity and high toxicity. Development of cancer vaccines may be the holy grail, with the promise of high specificity, low toxicity and prolonged activity. Despite years of R&D and enhanced understanding of tumor immunology, a reproducible survival benefit has proved elusive, leaving the market wide open.


Scope

  • Examination of cancer vaccine pipeline with in-depth clinical and commercial profiles of Phase III candidates, incorporating Datamonitor opinion
  • Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of Phase III agents to 2014
  • Analysis of the cancer vaccine market, identifying developmental, manufacturing, logistical, regulatory and commercialization issues
  • Insight and commentary from qualitative interviews with oncology opinion leaders in the US and Europe


    • Report Highlights
    Given the relative immaturity and lack of precedence of the cancer vaccine market, an entirely new set of clinical and strategic issues has been brought to light. Significant hurdles need to be overcome, both on a local and international level before successful commercialization of a cancer vaccine can be realized.

    Cancer vaccines will complement current treatment approaches, rather than serve as a replacement. If the full potential of cancer vaccines is realized, the need for multiple-lines of treatment may be eliminated, ultimately driving the cost of oncology care down.

    The majority of the cancer vaccine pipeline constitutes off-the-shelf vaccines rather than personalized or cell-based formulations. Although the former are capable of mass manufacture, the latter have shown greater clinical benefit, but encompass a more complex and expensive formulation. It is unclear which class will reach the market first.


    Reasons to Purchase

  • Identify the key cancer vaccines and cell therapies in the current pipeline based on sales forecasts to 2014 and Datamonitor drug assessments
  • Assess opportunities and risks for cancer vaccines and cell therapies within the oncology market
  • Optimize development and commercialization of cancer vaccines by improving strategic planning

    • Table of Contents

    Other users found this report page using the following search terms: cancer vaccine cell therapy oncology Dendritic Cell cervical cancer melanoma cancer vaccines pipeline types four big tumor department medarex ign

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.